VEGFA and glioblastoma: Anti-angiogenic therapy for GBM has been developed prominently in the form of bevacizumab, a recombinant human anti-VEGF-A monoclonal antibody that acts primarily by neutralizing VEGF to block its binding to VEGF receptors on endothelial cells.